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Available online 5 September 2017Anti-citrullinated Protein Antibodies (ACPA) are excellent markers for Rheumatoid arthritis (RA) and are postu-
lated to have a pathogenic role in the disease process. A multistep model for the evolution of the ACPA response
inRAwasproposed inwhich an initial break of tolerance causes, as “first hit”, “silent” production of ACPAwithout
any clinical symptoms. Themodel further proposes that the ACPA immune responsematures upon a certain (un-
known) trigger, a “second hit”, which leads to epitope spreading, an increase in ACPA titres and extended isotype
usage before clinical RAmanifestations. These occurrences are indicative of an expansion of the citrulline-specific
B cell response, though ACPA remain of low avidity even in established disease. This persistence of low avidity is
puzzling, as the typical signs ofmaturation of the immune response seem to be uncoupled from the classical pro-
cess of affinity maturation. In fact, it suggests that B cells expressing ACPA could bypass selection mechanisms
that otherwise control the expansion of auto-reactive B cells. In the established, chronic phase, we recently
found that ACPA-IgG are extensively glycosylated in the variable (Fab) domain.More than 90% of ACPA-IgGmol-
ecules carry Fab glycans that are highly sialylated. This molecular feature is striking and may provide a missing
link in our understanding of the maturation of the ACPA immune response. This review, therefore, describes
the current knowledge about ACPA Fab glycosylation in the pathogenesis of RA.), l.hafken
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Rheumatoid arthritis (RA) is a chronic autoimmune disease charac-
terized by systemic and persistent inflammation of the synovium
which can lead to joint damage, bone destruction and, ultimately, may
cause disability and increasedmortality [1]. Around 0.5–1% of the west-
ern population is affected by RAwith a higher incidence amongwoman
and upon increased age [1,2]. Although it is not yet understoodwhat ex-
actly drives RA pathogenesis, genetic and environmental risk factors are
thought to contribute to the development of RA.
1.2. Autoantibodies in RA
An important hallmark of RA is the presence of autoantibodies.
Around 50–80% of patients with RA harbour either one or multiple au-
toantibodies [1]. Rheumatoid factor (RF) was the first autoantibody dis-
covered to correlate with RA and is included in the current RAscheid@lumc.nl
mc.nl (R.E.M. Toes).
n open access article underclassification criteria [3,4]. RF are directed against the Fc tail of the im-
munoglobulin G (IgG) molecule and thought to exert a pathogenic ef-
fector mechanism via the formation of immune complexes, the
activation of complement and the subsequent induction of inflammato-
ry mediators [5]. However, RF are not specific for RA as they are also
common in chronic and infectious diseases, and in healthy individuals
[6]. In addition to RF, antibodies against posttranslational modifications
can be found in the sera of patients with RA, such as anti-carbamylated
protein (anti-CarP) antibodies and Anti-citrullinated Protein Antibodies
(ACPA). Anti-CarP antibodies recognize proteins which are
carbamylated, a process leading to the chemical conversion of lysine
to homocitrulline [7]; ACPA, instead, recognize proteins that are
citrullinated, a process in which the positively charged amino acid argi-
nine is converted to a neutral citrulline by peptidyl arginine deiminase
(PAD) enzymes [8]. Importantly, ACPA are highly specific for RA and
are strongly associated with arthritis, severe joint destruction during
the course of the disease and lower remission rates [9,10]. Also histolog-
ically, ACPA-positive disease differs from ACPA-negative disease [11].
Furthermore, ACPA are very useful in predicting the onset of RA as
ACPA can be present years before first clinical disease manifestations
[12,13]. Also ACPA are now included in the 2010 EULAR/ACR classifica-
tion criteria for RA [14]. All together, these observations have led to the
general assumption that ACPA may play a crucial role in RAthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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unknown aspect. Here, we discuss how a novel molecular feature of
ACPA could contribute to the pathogenic immune response in RA.
2. Maturation of the ACPA response
2.1. The two-hit model of ACPA-positive RA
The development of ACPA-positive RA is thought to be a multistep
processwhich is described here by a two-hit model [15]. Environmental
and stochastics events (“first hit”) may drive the initial break of toler-
ance leading to ACPA production which can precede the onset of RA
for yearswithout signs of clinical symptoms [16]. Upon a certain trigger,
citrulline-specific B cells may receive T cell help inducing an inflamma-
tory autoimmune response. Because of this “second hit”, the ACPA re-
sponse matures, an event strongly associated with imminent onset of
arthritis.
2.2. The HLA association of ACPA-positive RA
The strongest genetic risk factor associated with RA is found within
genes encoding certain HLA class II molecules, specifically HLA-DR.
Within the third hypervariable region of the HLA-DRB1 chain there is
a common amino acid sequence, known as the shared epitope, identi-
fied as susceptibility epitope for RA [17]. It is hypothesized that the pos-
itively charged amino acids of the shared epitope favour binding to
negatively or neutrally charged amino acids thereby preferring binding
of citrullinated antigens over arginine residues [18]. Importantly, the
shared epitope predisposition is only associated with ACPA-positive
RA, not with ACPA-negative disease [19–21]. As HLA is involved in the
interaction of T- to B-cell responses, it is conceivable that T cells contrib-
ute to the maturation of the ACPA response, possibly via T cell help to
citrulline-specific B cells. Supporting this hypothesis, a recent paper
identified unexhausted, activated T ‘peripheral helper’ cells in the joint
of RA patientswhich expressed factors enabling help for B cells, directed
migration to the inflamed site and induced plasma cell differentiation
[22].
2.3. Expansion of the ACPA response
While HLA shared epitope alleles are associated with ACPA-positive
RA, they are not associated with the presence of autoimmunity/ACPA in
health [21,23]. Therefore, it was suggested that HLA molecules contrib-
ute to the “second hit” rather than the “first hit” of the two-hit model,
thereby increasing the range and intensity of the ACPA immune re-
sponse. A role for T cells as drivers of the activation of citrulline-
specific B cells and of thematuration of the ACPA response is supported
by the increase in ACPA titre, isotype switching and antigen recognition
profile shortly before clinical onset of RA [13,24–26]. However, ACPA are
highly cross-reactive towards different citrullinated proteins and, unlike
antibodies against recall antigens, ACPA are of low affinity. This indi-
cates that citrulline-specific B cells might not primarily be selected on
affinity for their cognate antigens, but on different selection mecha-
nisms in or outside of germinal centers [27–30].
3. Variable domain glycosylation of ACPA
3.1. Introduction of IgG glycosylation
The stability and biological activity of antibodies are influenced byN-
glycosylation of the antibody Fc region [31,32]. N-glycans can be incor-
porated within the IgG molecule when the N-glycosylation consensus
sequence Asn-X-Ser/Thr (N-X-S/T, where X ≠ P) is present. IgG mole-
cules have two conventional biantennary N-linked Fc glycans attached
to asparagine at position 297 in the CH2 region of the heavy chain
[33]. Glycans are highly dynamic and may display a modifiedoligosaccharide composition dependent on physiological and patholog-
ical conditions. Previously, we and others have demonstrated that
ACPA-IgG in RA have a pro-inflammatory Fc glycosylation pattern
with reduced galactosylation and sialylation levels, if compared to
non-ACPA IgG [34,35]. Interestingly, this ACPA phenotype started to de-
velop around three months before clinical onset of RA [36].
In addition to Fc glycosylation, however, few human genes encoding
V-segments of the antigen-binding fragment (Fab) also harbour N-
glycosylation consensus sequences [37]. These allow for the presence
of N-glycans in the Fab domain. Moreover, Fab glycosylation can be
found in the antibody variable domain as a consequence of somatic
hypermutation which, during antibody maturation, can generate de
novo N-glycosylation sites [38]. These N-glycosylation motifs are infre-
quently found in normal B cells, but are commonly observed in immu-
noglobulins of patients with follicular lymphoma, especially in diffuse
large B-cell lymphoma and Burkitt's lymphoma [39,40]. Interestingly,
also IgG of RA patients were observed to have an increased presence
of Fab glycans compared to IgG from healthy donors [41].
3.2. ACPA Fab glycosylation
In this context, we recently identified a novel molecular feature of
ACPA. ACPA of the IgG isotypewere shown to be extensively glycosylat-
ed in the Fab region. These Fab glycans were found on both heavy and
light chain variable domains [42]. In fact, while ~15–25% of convention-
al IgG antibodies harbour Fab glycans, we estimated thatmore than 90%
of ACPA-IgG molecules carry Fab glycans [37,43]. ACPA-IgG isolated
from synovial fluid, the site of inflammation, could even exceed 100%
Fab glycosylation implying that multiple glycans can be attached to
the variable domain [43]. Detailed analysis of the glycosylation profile
further revealed that these ACPA-IgG harbour N-linked glycans that
are highly sialylated. This glycosylation profile of ACPA-IgG,which com-
prises the full range of biantennary glycan residues, could indicate that
ACPA Fab glycans are relatively easily accessible to glycosyltransferases.
Although we could not identify a comparable degree of Fab glycosyla-
tion for several other autoantibodies, it is yet unknown if Fab glycans
are a molecular feature that is specific for ACPA or that it represents
the type of autoimmune response that is generated [42]. Therefore, fur-
ther research is needed to determine the specificity of Fab glycans for
ACPA or other autoantibodies in RA. To understand more about the or-
igin of the extensive glycosylation of ACPA-IgG, ACPA-IgG variable do-
mains were analysed by mass spectrometry. This identified N-
glycosylation sites that were not encoded in the germline sequence,
but most likely introduced by somatic hypermutation [42]. Moreover,
in contrast to ACPA-IgG, we found indications that ACPA-IgM have no
additional Fab glycans [44]. All together, these results strongly suggest
that the extensive presence of sialylated N-glycans in the ACPA-IgG
Fab domains results from somatic hypermutation during maturation
of the ACPA response. It also provides an argument for the hypothesis
that the maturation of the ACPA response is dependent on T-cell help
which may contribute to the breach of tolerance checkpoints and the
maturation of citrulline-specific B cells in RA.
3.3. Functionality of ACPA Fab glycosylation
So far, it is unknown what role Fab glycans play in the functionality
of ACPA-IgG. Generally, glycans in the antibody variable domain have
been implicated tomodulate several functions in differentways. For ex-
ample, Fab glycans located close to the antigen binding site may affect
antigen binding [37]. Indeed, we have demonstrated that Fab glycans
on monoclonal ACPA may influence antigen binding, as depletion of
the variable domain glycans enhanced or decreased binding to the
CCP2 antigen, albeit to a limited extent [42]. Another important func-
tionality reported for glycans is the interaction with lectins. One hy-
pothesis is that introduction of Fab glycosylation in the B cell receptor
(BCR) via somatic hypermutation allows interaction of the BCR with
36 A.C. Kempers et al. / Clinical Immunology 186 (2018) 34–37lectins in the germinal center and thereby provide survival signals to
self-reactive B cells [45]. This phenomenon has been reported before
in follicular lymphoma where the interaction of lymphoma cells with
lectins free these cells from dependence on antigen and enhance the
survival through selection based on glycan interaction [39,45,46]. Be-
cause of the abundant presence of terminally sialylated Fab glycans on
ACPA-IgG and the overall low affinity of ACPA-IgG compared to conven-
tional recall antigens [27,43], it is possible that B cells producing Fab gly-
cosylated ACPA could have a survival advantage through selection
based on the presence of N-linked Fab glycans rather than on affinity
for their cognate antigen.
4. Conclusion
ACPA variable domain glycosylation is a recently reported novelmo-
lecular feature of ACPA-IgG. Almost all ACPA-IgG molecules were found
to carry these highly sialylated Fab glycanswhereas non-ACPA IgG and a
selected group of other autoantibodies analysed thus far did not show
this feature. This indicates that extensive Fab glycosylation is a specific
feature of ACPA-IgG in RA and could therefore be used as a biomarker
in ACPA-positive disease. The introduction of ACPA Fab glycans is likely
the result of somatic hypermutation during maturation of the ACPA re-
sponse. This observation, together with the finding that ACPA-IgM has
no additional Fab glycans, and the strong HLA association with ACPA-
positive RA implies that the introduction ofN-glycans in the variable do-
main is dependent on T cell help in or outside the germinal center.
Moreover, this process could contribute to the breach of tolerance
checkpoints during the “second hit” of the two-hit model for the devel-
opment of ACPA-positive RA. However, this does not exclude the possi-
bility that ACPA-IgG Fab glycans accumulate over time by multiple
“hits” or that someACPAmay carry Fab glycans from the start. Although
the function of ACPA Fab glycosylation in the pathogenesis of RA re-
mains to be determined, there are hints towards the involvement of
Fab glycans in the selection and survival of low affinity citrulline-
specific B cells. Further research is needed to determine the specificity
of Fab glycosylation in RA, and to gain insight in the biological processes
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